1. Home
  2. VSTM vs TECX Comparison

VSTM vs TECX Comparison

Compare VSTM & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verastem Inc.

VSTM

Verastem Inc.

HOLD

Current Price

$4.30

Market Cap

470.7M

Sector

Health Care

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$28.53

Market Cap

554.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSTM
TECX
Founded
2010
2019
Country
United States
United States
Employees
N/A
60
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
470.7M
554.1M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
VSTM
TECX
Price
$4.30
$28.53
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
5
Target Price
$16.50
$75.20
AVG Volume (30 Days)
2.1M
211.4K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
17.49
N/A
EPS
N/A
N/A
Revenue
$30,914,000.00
N/A
Revenue This Year
$282.64
N/A
Revenue Next Year
$72.25
N/A
P/E Ratio
N/A
N/A
Revenue Growth
209.14
N/A
52 Week Low
$4.00
$14.39
52 Week High
$11.25
$35.99

Technical Indicators

Market Signals
Indicator
VSTM
TECX
Relative Strength Index (RSI) 33.10 47.71
Support Level N/A $27.39
Resistance Level $6.67 $31.17
Average True Range (ATR) 0.33 1.81
MACD -0.09 0.01
Stochastic Oscillator 13.81 41.25

Price Performance

Historical Comparison
VSTM
TECX

About VSTM Verastem Inc.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: